Why do some MGUS or smoldering myeloma patients without symptoms progress from these early conditions to active myeloma? Myeloma researcher Elisabet Manasanch, MD of the MD Anderson Cancer Center is running a study to better understand factors that relate to progression. Questions she wants answered include: Why do some patients progress to actual myeloma? Is there something we can do about progression? Who is more likely to progress?
Potential markers that could affect progression include:
In the study, patients at MD Anderson will donate samples and take imaging tests to assess the progression of the disease:
After 3 years, patients will be followed every 6-12 months thereafter.
The study will first look at the following primary outcomes over the 3-year period:
Secondarily, the study will look at these additional outcomes over the 3-year period:
Other outcomes will be reviewed that include:
To learn more about this clinical trial on HealthTree or to get help joining this study, please call 1-800-709-1113.
about the author
Andrea Robles is an International Medical Graduate, part of Healthtree’s patient navigator staff. She is committed to patient’s global wellness and finding a cure through research. She’s also a wife and mom of 3.